Clinical-stage biopharmaceutical company developing therapies for metabolic diseases and non-alcoholic steatohepatitis (NASH).
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical firm based in San Mateo, California, specializes in developing therapeutics known as fatty acid synthase (FASN) inhibitors. These innovative treatments are designed to address diseases stemming from dysfunctional metabolic pathways prevalent in the United States.
The company's primary focus centers on Denifanstat, its leading drug candidate. Denifanstat is a once-daily oral medication that functions as a selective FASN inhibitor. It is specifically intended for the treatment of metabolic dysfunction associated with steatohepatitis, offering a potential breakthrough in managing this challenging condition.
In addition to Denifanstat, Sagimet Biosciences is advancing TVB-3567, another FASN inhibitor tailored for the treatment of acne. The company also pursues various oncology programs aimed at leveraging FASN inhibition for therapeutic benefits in cancer treatment.
Founded in 2006 under the name 3-V Biosciences, Inc., the company rebranded as Sagimet Biosciences Inc. in August 2019 to better reflect its evolving focus and strategic direction in biopharmaceutical innovation. Sagimet Biosciences continues to drive forward with its commitment to developing novel treatments that address significant unmet medical needs through innovative science and rigorous clinical research.